Safety of intranasal insulin administration in patients undergoing cardiovascular surgery: An open-label, nonrandomized, dose-escalation studyCentral MessagePerspective
Uloženo v:
| Název: | Safety of intranasal insulin administration in patients undergoing cardiovascular surgery: An open-label, nonrandomized, dose-escalation studyCentral MessagePerspective |
|---|---|
| Autoři: | Yosuke Nakadate, MD, PhD, Akiko Kawakami, MD, PhD, Takeshi Oguchi, MD, PhD, Keisuke Omiya, MD, PhD, Hiroyuki Nakajima, MD, PhD, Hiroshi Yokomichi, MD, PhD, DPH, Hiroaki Sato, MD, PhD, Thomas Schricker, MD, PhD, Takashi Matsukawa, MD, PhD |
| Zdroj: | JTCVS Open, Vol 17, Iss , Pp 172-182 (2024) |
| Informace o vydavateli: | Elsevier, 2024. |
| Rok vydání: | 2024 |
| Sbírka: | LCC:Diseases of the circulatory (Cardiovascular) system LCC:Surgery |
| Témata: | cardiac surgery, hypoglycemia, intranasal insulin administration, serum insulin concentration, postoperative delirium, Diseases of the circulatory (Cardiovascular) system, RC666-701, Surgery, RD1-811 |
| Popis: | Objective: This study aimed to determine the maximum safe dose of intranasal insulin administration during cardiac surgery. Methods: This open-label, Phase 1, single-center, dose-escalation clinical trial recruited patients scheduled to undergo elective cardiac surgery or major vascular surgery requiring cardiopulmonary bypass between February and September 2021. They were grouped into 5 dose-escalation cohorts and administered 0, 40, 80, 160, and 240 IU insulin (n = 6 in each group) via a metered nasal dispenser after the induction of general anesthesia. Blood samples were collected at 10-minute intervals for the first 60 minutes and at 30-minute intervals thereafter. Hypoglycemia was defined as a blood glucose level |
| Druh dokumentu: | article |
| Popis souboru: | electronic resource |
| Jazyk: | English |
| ISSN: | 2666-2736 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2666273623004175; https://doaj.org/toc/2666-2736 |
| DOI: | 10.1016/j.xjon.2023.11.020 |
| Přístupová URL adresa: | https://doaj.org/article/049bafa0f0c84b1e8911dbe2b0625650 |
| Přístupové číslo: | edsdoj.049bafa0f0c84b1e8911dbe2b0625650 |
| Databáze: | Directory of Open Access Journals |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Objective: This study aimed to determine the maximum safe dose of intranasal insulin administration during cardiac surgery. Methods: This open-label, Phase 1, single-center, dose-escalation clinical trial recruited patients scheduled to undergo elective cardiac surgery or major vascular surgery requiring cardiopulmonary bypass between February and September 2021. They were grouped into 5 dose-escalation cohorts and administered 0, 40, 80, 160, and 240 IU insulin (n = 6 in each group) via a metered nasal dispenser after the induction of general anesthesia. Blood samples were collected at 10-minute intervals for the first 60 minutes and at 30-minute intervals thereafter. Hypoglycemia was defined as a blood glucose level |
|---|---|
| ISSN: | 26662736 |
| DOI: | 10.1016/j.xjon.2023.11.020 |